💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Spesolimab

CHEMBL4297911 Phase 4 承認済み Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Spesolimab is a humanized monoclonal antibody that blocks the interleukin-36 receptor (IL-36R), preventing signaling by the pro-inflammatory cytokines IL-36α, IL-36β, and IL-36γ, which drive keratinocyte-mediated inflammation in generalized pustular psoriasis (GPP). By inhibiting IL-36 receptor signaling, it rapidly suppresses the acute inflammatory cascade causing sterile pustule formation and systemic inflammation in GPP flares. It is approved for the treatment of GPP in adults and has orphan drug status for this rare condition.

治療領域

Psoriasis

作用機序

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Spesolimab is a humanized monoclonal antibody that blocks the interleukin-36 receptor (IL-36R), preventing signaling by the pro-inflammatory cytokines IL-36α, IL-36β, and IL-36γ, which drive keratinocyte-mediated inflammation in generalized pustular psoriasis (GPP). By inhibiting IL-36 receptor signaling, it rapidly suppresses the acute inflammatory cascade causing sterile pustule formation and systemic inflammation in GPP flares. It is approved for the treatment of GPP in adults and has orphan drug status for this rare condition.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Spesolimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297911. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.